PPARG and metabolic dysfunction-associated steatotic liver disease: Natural and synthetic PPARγ agonists have shown potential in the treatment of various liver diseases, including non‐alcoholic fatty liver disease (NAFLD), autoimmune hepatitis, liver fibrosis and hepatocellular carcinoma.54, 55